Immunotherapy has been a remarkable clinical advancement in the treatment of cancer. T
cells are pivotal to the efficacy of current cancer immunotherapies, including immune …

Long recognized as an evolutionarily ancient cell type involved in tissue homeostasis and
immune defense against pathogens, macrophages are being re-discovered as regulators of …

Immunotherapy has revolutionized cancer treatment, but efficacy remains limited in most
clinical settings. Cancer is a systemic disease that induces many functional and …

One of the defining characteristics of a pre-metastatic niche, a fundamental requirement for
primary tumor metastasis, is infiltration of immunosuppressive macrophages. How these …

Metastasis is the primary cause of cancer mortality, and cancer frequently metastasizes to
the liver. It is not clear whether liver immune tolerance mechanisms contribute to cancer …

Tumors are populated by antigen-presenting cells (APCs) including macrophage subsets
with distinct origins and functions. Here, we examined how cancer impacts mononuclear …

Although pyroptosis is critical for macrophages against pathogen infection, its role and
mechanism in cancer cells remains unclear. PD-L1 has been detected in the nucleus, with …

Immune checkpoint blockade therapy has become a major weapon in fighting cancer.
Antibody drugs, such as anti-PD-1 and anti-PD-L1, demonstrate obvious advantages such …

Programmed Death-1 (PD-1; CD279) is an inhibitory receptor induced in activated T cells.
PD-1 engagement by its ligands, PD-L1 and PD-L2, maintains peripheral tolerance but also …

Summary PD-1/PD-L1-checkpoint blockade therapy is generally thought to relieve tumor cell-
mediated suppression in the tumor microenvironment but PD-L1 is also expressed on non …